An overview of four studies of a continuous oral contraceptive (levonorgestrel 90 mcg/ethinyl estradiol 20 mcg) on premenstrual dysphoric disorder and premenstrual syndrome

摘要: Abstract Background This article presents an overview of four studies that evaluated a continuous oral contraceptive (OC) containing levonorgestrel (90 mcg) and ethinyl estradiol (20 mcg; LNG/EE) for managing premenstrual dysphoric disorder (PMDD) syndrome (PMS). Study Design Three randomized, double-blind, placebo-controlled trials one open-label, single-treatment substudy examined mean changes from baseline in the Daily Record Severity Problems (DRSP) or Penn Symptom Rating (DSR). Results Improvements DRSP DSR scores were observed, but results not consistent among studies. Mean percent improvement symptoms ranged 30% to 59% controlled 56% 81% open-label substudy. A large placebo effect was also observed Continuous LNG/EE yielded favorable safety profile. Conclusions These data, although consistent, indicate may reduce PMDD PMS, providing option women who are appropriate candidates OC as contraceptive, approved indication this medication.